country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-106698

Copy Link Print Information

Brovincamine

Brovincamine is an orally active slow Ca²⁺ channel blocker and vasodilator. Brovincamine reduces Ca²⁺ influx across the plasma membrane by blocking Ca²⁺ channels. Brovincamine inhibits catecholamine secretion, cholinergic function, autonomic parasympathetic nervous system activity, cerebrovascular resistance, and nerve stimulation-induced convulsive responses. Brovincamine induces cerebrovascular, coronary, and intracranial vasodilation, improves cerebral cortical microcirculation, enhances cerebral metabolic activity, and increases capillary clearance efficiency. Brovincamine can be used in research related to cerebral ischemic diseases, cardiac ischemic diseases, and normal-tension glaucoma.

For research use only. We do not sell to patients.

CAS No.: 57475-17-9
Formula: C₂₁H₂₅BrN₂O₃
Molecular Weight:433.35

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Brovincamine Chemical Structure

CAS No.: 57475-17-9

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Calcium Channel Isoforms :

In Vitro

Brovincamine (30-100 μM; 10 min) inhibits Carbamoylcholine (HY-B1208)-induced (IC₅₀ 30 μM) and high K⁺-induced (IC₅₀ 100 μM) catecholamine secretion and calcium influx in cultured bovine adrenal chromaffin cells, and its inhibitory characteristics vary with extracellular Ca²⁺ concentration depending on the secretagogue^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cardiovascular RegulationLocal Vascular Regulation

Cardiovascular Regulation

Brovincamine (6.4 mg/kg; intravenous injection; single administration) mildly inhibits the cardiovascular response to DMPP in spinal dogs^[2].
Brovincamine (2-4 mg/kg, intravenous injection; single/cumulative administration) slightly but dose-dependently inhibits ganglionic stimulant-induced tachycardia in spinal dogs^[2].

Local Vascular Regulation

Brovincamine (7.5 mg/kg/day; p.o.; daily administration; for 4 weeks) improves cortical cerebral capillary morphology in young adult rats and aged healthy rats by increasing the volume, length, and density of cortical cerebral capillaries while decreasing capillary diameter and intercapillary distance^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mongrel dogs (either sex, weighing 6-12 kg, spinal model)^[2]
Dosage:

6.4 mg/kg
Administration:

i.v.; single dose
Result:

Slightly inhibited the increases in blood pressure and heart rate induced by i.v. DMPP.

Animal Model:

Mongrel dogs (either sex, weighing 6-12 kg, spinal model)^[2]
Dosage:

2 mg/kg; 4 mg/kg
Administration:

i.v.; single dose; cumulative
Result:

Induced a slight but stepwise inhibition of tachycardia elicited by DMPP, BCH, and AT II delivered to cardiac sympathetic ganglia.
Significantly reduced positive chronotropic responses to AT II.

Animal Model:

OFA (Sprague Dawley) (female; 12 months, 36 months)^[4]
Dosage:

7.5 mg/kg/day
Administration:

p.o.; daily; 4 weeks
Result:

Reduced capillary diameter from 3.20 μm to 2.97 μm in 12-month-old rats.
Increased capillary volume fraction from 3.62% to 4.46% in 12-month-old rats.
Reduced mean intercapillary distance from 30.90 μm to 27.79 μm in 12-month-old rats.
Increased capillary length per unit cortex from 54.87 cm/mm³ to 69.03 cm/mm³ in 12-month-old rats.
Increased number of capillaries per measuring field from 20 to 23 in 12-month-old rats.
Reduced capillary diameter from 3.29 μm to 3.09 μm in 36-month-old rats.
Increased capillary volume fraction from 3.67% to 4.45% in 36-month-old rats.
Reduced mean intercapillary distance from 31.04 μm to 28.78 μm in 36-month-old rats.
Increased capillary length per unit cortex from 50.77 cm/mm³ to 71.15 cm/mm³ in 36-month-old rats.
Increased number of capillaries per measuring field from 19 to 23 in 36-month-old rats.

Related Protocols :

Chemical Information

CAS No. 57475-17-9
Molecular Weight 433.35
Formula C₂₁H₂₅BrN₂O₃
SMILES

C(C)[C@]12[C@]3(C=4N(C=5C(C4CCN3CCC1)=CC=C(Br)C5)[C@](C(OC)=O)(O)C2)[H]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Morita K, et al. Inhibitory action of brovincamine on catecholamine secretion from cultured bovine adrenal medullary cells: possible relation to its blocking action on Ca2+ channels. Biochem Pharmacol. 1991 Jun 21;42(1):190-2.

[2]. Kushiku K, et al. Effects of brovincamine on the autonomic nervous function in the dog and rat. Journal of pharmacobio-dynamics. 1984 Mar;7(3):177-85.

[3]. Sawada A, et al. Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma. Ophthalmology. 1996 Feb;103(2):283-8.

[4]. Meier-Ruge W, et al. Effects of brovincamine on the stereological parameters of corticocerebral capillaries. Life sciences. 1987 Mar 09;40(10):943-9.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote